title: Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients.
abstract: BACKGROUND
  The effects of antidepressants on mood, cognition and the daily activities of Alzheimer patients are ambiguous. The effects of antidepressants SSRIs (serotonin specific reuptake inhibitors), TCAs (tricyclic antidepressants) and SNRIs (serotonin-norepinephrine reuptake inhibitors), in particular, are unknown.
  
  
  OBJECTIVE
  This study aimed to compare the effects of sertraline, venlafaxine and desipramine on depression, cognition and the daily activities of Alzheimer patients.
  
  
  METHODS
  This randomized double-blind trial was approved by the Research and Ethics Committees of Mashhad University of Medical Sciences. 59 moderate Alzheimer patients with major depressive disorder were randomly divided into 3 groups (sertraline, venlafaxine and desipramine), treated for 12 weeks (150 mg maximum dose) and assessed by the Hamilton Depression Test (HRSD), the Mini Mental State Examination (MMSE) and the Barthel index at the week 0 and the 2(nd), 4(th), 8(th), 12(th) weeks thereafter. Data were analyzed by SPSS software, using ANOVA and paired t-tests.
  
  
  RESULTS
  In the sertraline group, the results of all 3 tests, HRSD, MMSE and Barthel, in the 12(th) week showed significant improvements in comparison to the baseline (P<0.05 in all 3 tests). In the venlafaxine group, the results of MMSE and Barthel revealed significant improvements (P<0.05 in both tests). In the desipramine group, there was a significant improvement only in the Barthel test at the 12(th) week (P<0.05).
  
  
  CONCLUSIONS
  In this trial, sertraline treatment was associated with superior effectiveness in relation to depressive, cognitive, and behavioral symptoms.
authors: Psychiatry and Behavioral Sciences Research Center, lbn-e-Sina Hospital, Faculty of Medicine, Mashhad University of -Medical Sciences, Mashhad, Iran.
authors: N
authors: N
authors: Mokhber
authors: Psychiatry and Behavioral Sciences Research Center, lbn-e-Sina Hospital, Faculty of Medicine, Mashhad University of -Medical Sciences, Mashhad, Iran.
authors: E
authors: E
authors: Abdollahian
authors: Psychiatry and Behavioral Sciences Research Center, lbn-e-Sina Hospital, Faculty of Medicine, Mashhad University of -Medical Sciences, Mashhad, Iran.
authors: A
authors: A
authors: Soltanifar
authors: Psychiatry and Behavioral Sciences Research Center, lbn-e-Sina Hospital, Faculty of Medicine, Mashhad University of -Medical Sciences, Mashhad, Iran.
authors: R
authors: R
authors: Samadi
authors: General Practice, Mashhad, Iran.
authors: A
authors: A
authors: Saghebi
authors: General Practice, Mashhad, Iran.
authors: M B
authors: MB
authors: Haghighi
authors: Faculty of Dentistry, Institute of Health Policy, Management and Evaluation of Faculty of Medicine, University of Toronto, Toronto, Canada.
authors: A
authors: A
authors: Azarpazhooh
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology*; D000928:Antidepressive Agents / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000453:epidemiology*; D003891:Desipramine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020280:Sertraline / Q000627:therapeutic use*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D000069470:Venlafaxine Hydrochloride; D020280:Sertraline; D003891:Desipramine